Title:
Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
Document Type and Number:
Japanese Patent JP7174522
Kind Code:
B2
Abstract:
The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
Inventors:
Brentgens, Renier Jay.
Smith, Eric El.
Liu, Chen
Smith, Eric El.
Liu, Chen
Application Number:
JP2017529750A
Publication Date:
November 17, 2022
Filing Date:
December 04, 2015
Export Citation:
Assignee:
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics, Incorporated
Eureka Therapeutics, Incorporated
International Classes:
C07K19/00; A61K35/17; A61K35/545; A61K39/395; A61K48/00; A61P35/00; A61P35/02; C07K14/705; C07K16/30; C12N5/0735; C12N5/0783; C12N5/0789; C12N5/10; C12N15/13; C12N15/62
Domestic Patent References:
| JP2017513818A |
Foreign References:
| WO2014191128A1 | ||||
| WO2006039238A2 |
Attorney, Agent or Firm:
Shusaku Yamamoto
Morishita Natsuki
Morishita Natsuki